Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer Patients
Despite the underutilization of chemotherapy for hormone receptor-positive, Her2-negative, pN2 patients, it was associated with improved OS for all 21-gene panel risk groups. These results support the existing standard of chemotherapy for this population, although omission could be considered in patients over 70 years of age.
Authors
- E. Brian Butler (ORCID: https://orcid.org/0000-0002-4439-1870)
- Dharamvir Jain (ORCID: https://orcid.org/0000-0003-3482-8001)
- Bin S. Teh (ORCID: https://orcid.org/0000-0003-1456-9444)
- Akshay Ramakrishnan
- Waqar Haque (ORCID: https://orcid.org/0000-0001-9364-2966)
- Niva Mangalampalli
- Vivek Verma (ORCID: https://orcid.org/0000-0002-5863-6023)
- Kai Sun (ORCID: https://orcid.org/0000-0002-4778-4549)
- Mary R. Schwartz (ORCID: https://orcid.org/0000-0002-8915-4844)
- Candy Arentz
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Methodist Hospital (US)
- The University of Texas Medical Branch at Galveston (US)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.21873/anticanres.17492
- Primary Topic
- Multiple and Secondary Primary Cancers
- Type
- article
- Field-Weighted Citation Impact
- 0.00